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Complex biosynthetic enzymes such as polyketide synthases make mistakes. In this issue of Chemistry &
Biology, Jensen et al. report that a discrete family of acyltransferases is responsible for error correction,
hydrolyzing key biosynthetic intermediates from a multi-enzyme complex. This activity might find use in
understanding polyketide biosynthesis, particularly in uncultivated organisms and in tailoring the synthesis
of small molecules.Many natural products are made by type I
polyketide synthase (PKS) pathways, in-
cluding important drugs such as erythro-
mycin (antibacterial), and rapamycin
(immunosuppression). Genome-based
prediction of PKS products is also
becoming increasingly important in drug
discovery. PKSs are large enzymes that
harbor multiple discrete enzymatic
domains (Hertweck, 2009). A malonate
unit or a derivative thereof is added by
each functional ‘‘module,’’ extending the
polyketide chain by two carbon atoms.
At each module, several optional tailoring
domains control the final reduction state
of the unit added by the preceding
module, giving rise to structural diversity.
From early examples it was believed
that the order of reactions followed a strict
co-linearity, both in gene and domain
organization, and that the products of
gene clusters could be easily predicted.
However, as more PKS pathways have
been described, it has become clear that
the co-linearity rules are not absolute and
there remains a great deal to learn about
how these pathways work. A particularly
intriguing group is the recently described
trans-acyltransferase (AT) group of PKSs
(Piel, 2010), where the ATs are not found
in the main PKS but are on separate
proteins that act in trans. These pathways
have many peculiarities that deviate from
the common ‘‘textbook’’ conception of
PKSs that often make it difficult to anno-
tate gene clusters. For example, they
frequently have seemingly superfluous
domains and deviations from co-linearity,
and their products have unusual chemical
features.While cis-AT PKS pathways typi-
cally incorporate double bonds in an a-b
trans configuration, cis and b-g double
bonds are often seen in trans-AT PKS
systems. Another hallmark of trans-ATPKS pathways is the inclusion of carbon
branches at the b position, i.e., the former
position of a carbonyl group in a malonate
unit. The leinamycin pathway (Cheng
et al., 2003) (see Figure 1) is a good
example of this, because it features both
an unusual order of modules and a ‘‘type
B’’ dehydrating dimodule (Piel, 2010) that
may introduce two double bonds, one cis
and one trans. It is worth noting that the
timing of the two dehydrations by such
a dimodule is unknown (Piel, 2010), and
they could either both occur at module 4
or sequentially starting at module 3.
Because of the unusual nature of trans-
AT PKS pathways, there are still many
biochemical questions to answer about
how they work, with each new pathway
raising new questions. This increases the
challenges of characterizing new path-
ways, especially when the structure of
the product is not known. A significant
number of trans-AT pathways are found
in uncultured symbionts (see Table 1),
identified from metagenomic analysis.
For some time, it has been postulated
that symbiotic bacteria produce many
natural products that were originally
attributed to marine invertebrates and
other animals (Piel, 2004). Indeed, these
compounds may be an important dimen-
sion of the symbiotic relationship between
animals and associated bacterial commu-
nities. When studying pathways from
uncultured or unidentified bacteria, bio-
chemical characterization of proteins
becomes especially challenging as the
native system is not available. Heterolo-
gous expression has been difficult, espe-
cially for PKSs where the entire pathway
can easily be in excess of 120 kbp.
One of the many mysteries surrounding
trans-AT systems is the inclusion of more
than one AT domain in certain pathways.Chemistry & Biology 19, March 23, 2012Some previously obtained genetic data
provided tantalizing clues about the role
of these dual ATs, but much remained
uncertain about their biochemical func-
tions. For example, in the case of mupiro-
cin, it has been shown that one of the AT
domains is essential to compound pro-
duction, whereas deletion of the other
leads to reduced product titers (Lopanik
et al., 2008). In this issue of Chemistry &
Biology, Jensen et al. (2012) report the
role of the second AT domain in trans-AT
PKS pathways. This work links the
second AT to a curious phenomenon: in
some pathways, inactivation of the thio-
esterase (TE) domain in the last module
does not simply prevent the final polyke-
tide product from being released from
the PKS enzyme, as expected, but rather
leads to the release of shorter intermedi-
ates from multiple modules. This effect
has been reported in three trans-AT
PKSs, bacillaene (Moldenhauer et al.,
2010), rhizoxin (Kusebauch et al., 2010),
and mupirocin (Wu et al., 2008), all of
which make use of multiple AT domains.
Jensen et al. (2012) show that the second
AT, which they term ‘‘AT2,’’ does not load
extender units onto ACP domains, but
instead cleaves already loaded intermedi-
ates that are longer and bulkier than ma-
lonyl-ACP. They therefore propose that
the AT2 acts as a ‘‘proofreader’’ for these
pathways, and that it cleaves stalled
intermediates.
A similar process of proofreading is
known in some cis-AT PKS and NRPS
pathways, where type II TEs cleave acyl
chains from ACPs where aberrant decar-
boxylation has occurred or an incorrect
unit has been incorporated (Kim et al.,
2002; Schwarzer et al., 2002). In contrast
to the action of ‘‘AT2’’ domains, type II
TEs prefer short acyl chains and thereforeª2012 Elsevier Ltd All rights reserved 309
Figure 1. A Future Application for the Proofreader?
Trans-AT polyketide synthase (PKS) leinamycin pathway (Cheng et al., 2003), showing hypothetical intermediates that would be detected upon introduction of an
AT2 protein, such as PedC, and mutation of the terminal thioesterase (TE) on LnmJ. Detection of the boxed intermediate would show that dimodule four dehy-
drates the intermediate made by module 3, as opposed to carrying out two dehydrations after extension at module 4. Unusual features of this pathway are as
follows: (1) LnmQ loads D-Ala rather than L-Ala with later epimerization; (2) unusualmodule order, for example the ACPdomain is in themiddle ofmodules 2 and 4,
and there is an extra ACP in module 6; (3) module 4 is split across two PKS proteins and is proposed to introduce two double bonds, one cis and one trans (Piel,
2010); and (4) unique post-PKS transformations give rise to a 1-oxo-1,2-dithiolan-3-one moiety.
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intermediates (Schwarzer et al., 2002).
Intriguingly, in the rifamycin pathway, a
cis-AT type PKS has been observed to
release chain intermediates when the
terminal TE is mutated (Yu et al., 1999).
This gene cluster contains a type II TE
(RifR), whose deletion causes a reduction
in compound yield (Kim et al., 2002).
However, there is also an unannotated
gene in the rifamycin gene cluster, orf20
(AAG52990), that is a standalone AT.
In light of the work of Jensen et al.
(2012) it would be interesting to determineTable 1. Polyketides Made by trans-AT PKS
Compound(s) Host
Pederin Paederus and Paederidus spp.
Onnamides,
theopederins
Theonella swinhoei, Trachychaedu
laevispirulifer, Discodermia sp.
Bryostatins Bugula neritina, Amathia convoluta
Rhizoxin Rhizopus microsporus
Psymberin Psammocinia aff. bulbosa
310 Chemistry & Biology 19, March 23, 2012whether orf20 or another AT is involved in
intermediate release.
Importantly, Jensen et al. (2012) found
that the standalone AT2 PedC was also
able to cleave a hexanoyl starter unit
from an ACP taken from a fungal iterative
PKS. This opens up the possibility that
enzymes such as PedC could be used
to induce bacillaene-like intermediate
ejection into even distantly related path-
ways if the TE is disrupted. For example,
PedC coexpression with the leinamycin
pathway could shed some light on the
mechanism of dehydration by dimodulePathways Found in Uncultured Symbionts
Symbiont
Pseudomonas sp.
s Unknown
Candidatus ‘‘Endobugula sertula’’
Burkholderia rhizonica, B. endofungorum
Unknown
ª2012 Elsevier Ltd All rights reserved4 (see Figure 1). If the enzyme proves to
be tolerant enough to ACP substrates,
this could be an extremely useful bio-
chemical tool to probe the function of
cryptic PKS pathways. Enzymes such as
PedC, therefore, could prove valuable
in the biochemical characterization of
trans-AT PKSs where expression of the
whole pathway or knockout experiments
are not feasible, such as when the genes
belong to an uncultured symbiont.REFERENCES
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The challenge of studying complex protein networks in whole animals has driven the development of
new methods for manipulating protein function with spatial and temporal precision. A novel combination
of chemical and genetic protein regulation (Rodriguez and Wolfgang, in this issue of Chemistry & Biology)
achieves levels of control that will revolutionize the study of protein function.Identifying the function of a protein has
often relied on characterizing the impact
of naturally occurring or directed muta-
tions in the gene encoding that protein.
Protein functions were first elucidated
in microorganisms through the use of
temperature-sensitive alleles, mutations,
and deletions. In whole organisms, devel-
opmental biologists successfully de-
scribed a variety of complex protein
networks by designing ways to perturb
specific proteins in model organisms
and characterizing the resulting pheno-
types. The past 20 years have seen the
advent of homologous recombination
techniques in mice that enable protein
regulation through mutations, transcrip-
tional control, and RNAi (Thomas and
Capecchi, 1990). However, many of
these technical advances have serious
drawbacks. Attenuated gene expression,
gene knockouts, and mutations in mam-
mals frequently have lethal or detrimental
outcomes during early development that
prevent exploration of protein function
on whole animal physiology and at later
stages. Although RNAi has proven to be
a powerful knockdown technique, de-
signing functional RNAi probes can beproblematic, because it is difficult to
predict if a given sequence will attenuate
mRNA levels. Further, changes in mRNA
levels do not always produce a corre-
sponding change in protein levels. De-
spite these challenges, it is critical to
develop approaches that study the func-
tion of proteins in whole animals because
complicated and overlapping factors
such as secreted factors, cell-cell interac-
tions, and metabolic state most certainly
impact protein function but are impos-
sible to replicate in less complex systems.
Therefore, the future of functional protein
studies in whole organisms lies in devel-
oping sophisticated tools that reversibly
regulate proteins in a specific time and
place.
Our understanding of complex biolog-
ical networks would particularly benefit
from improved capabilities in controlling
the levels of any given protein with fine-
tuned precision. For example, studies of
lipid metabolism have been especially
challenging because there are often
many similar proteins (as defined by
enzymatic properties) in the vertebrate
genome that can act in concert with func-
tionally-related lipid-modifying proteins.Elucidating the function of these proteins
would be facilitated by designing experi-
ments that discretely control expression
of a protein. To this end, small molecule-
mediated protein regulation has been
the most successful approach to tempo-
rally regulate proteins due to its broad
applicability to almost any protein of
study, its specificity in targeting, and its
reversibility. The basic principle of this
approach is to fuse inherently unstable
protein domains to a protein of interest,
thereby conferring instability to the entire
fusionconstruct. Introducingabiologically
inert small molecule that binds specifically
to the unstable protein domain in the
fusion construct subsequently stabilizes
the fusion protein in a dose-dependent
manner, thereby effectively activating
the protein of interest. Reversal of this
process is achieved by removing the
small molecule. Several groups have
spent the better part of a decade modi-
fying and perfecting a small protein
domain of FK506 binding protein 12
(FKBP12) that can convey instability to
any protein to which it is fused (Stankunas
et al., 2003; Yang et al., 2000). Improve-
ments in high throughput structure-basedª2012 Elsevier Ltd All rights reserved 311
